[Expectation for the drug development activity in academia].
Recently many pharmaceutical industries aim at "academic-industrial alliances" to increase opportunities for new drug development. The form of the alliance is mainly a "center-based" one, but recently "open-type" alliance has also become popular. To promote effective collaboration between academia and industries, both parties should obtain clear understanding and support from society through compliance with the social requirement including accountability on the collaborative research and transparency on their relationship. In addition, clinical studies need to comply with the "Ethical Guideline for Clinical Research," or Good Clinical Practice (GCP). Pharmaceutical industries anticipate seeing the deliverables of academic research, and are working on realization of utilizing them in actual medicinal cases.
Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association, Tokyo, Japan. osamu-inagaki@jp.astellas.com
Osamu
O
Inagaki
D000047:Academies and Institutes; D035843:Biomedical Research / Q000941:ethics; D003299:Cooperative Behavior; D055808:Drug Discovery / Q000639:trends*; D004345:Drug Industry / Q000458:organization & administration; D007564:Japan